Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.

Hatton O, Phillips LK, Vaysberg M, Hurwich J, Krams SM, Martinez OM.

J Biol Chem. 2011 Oct 28;286(43):37368-78. doi: 10.1074/jbc.M111.255125. Epub 2011 Sep 9.

2.

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.

Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF.

Blood. 2011 Jan 13;117(2):530-41. doi: 10.1182/blood-2010-07-294249. Epub 2010 Oct 20.

3.

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.

Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB.

N Engl J Med. 2010 Sep 30;363(14):1303-12. doi: 10.1056/NEJMoa1000500. Epub 2010 Sep 22.

4.

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.

Suljagic M, Longo PG, Bennardo S, Perlas E, Leone G, Laurenti L, Efremov DG.

Blood. 2010 Dec 2;116(23):4894-905. doi: 10.1182/blood-2010-03-275180. Epub 2010 Aug 17.

5.

Therapeutic targeting of Syk in autoimmune diabetes.

Colonna L, Catalano G, Chew C, D'Agati V, Thomas JW, Wong FS, Schmitz J, Masuda ES, Reizis B, Tarakhovsky A, Clynes R.

J Immunol. 2010 Aug 1;185(3):1532-43. doi: 10.4049/jimmunol.1000983. Epub 2010 Jul 2. Erratum in: J Immunol. 2011 Aug 1;187(3):1516.

6.

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.

Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, Witzig TE.

Cancer. 2010 May 1;116(9):2201-7. doi: 10.1002/cncr.25005.

7.

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C.

Immunity. 2010 Jan 29;32(1):129-40. doi: 10.1016/j.immuni.2009.11.009. Epub 2010 Jan 14.

8.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.

Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.

9.

Novel human transitional B cell populations revealed by B cell depletion therapy.

Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, Looney RJ, Sanz I, Anolik JH.

J Immunol. 2009 May 15;182(10):5982-93. doi: 10.4049/jimmunol.0801859.

10.

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.

Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB.

Blood. 2009 Apr 2;113(14):3154-60. doi: 10.1182/blood-2008-07-166439. Epub 2008 Dec 18.

11.

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.

Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI.

Arthritis Rheum. 2008 May;58(5):1433-44. doi: 10.1002/art.23428.

12.

Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406.

Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, Grossbard EB, Clemens GR.

Toxicol Appl Pharmacol. 2007 Jun 15;221(3):268-77. Epub 2007 Mar 31.

PMID:
17490694
13.

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A.

J Immunol. 2007 May 15;178(10):6092-9.

14.

Space, selection, and surveillance: setting boundaries with BLyS.

Miller JP, Stadanlick JE, Cancro MP.

J Immunol. 2006 Jun 1;176(11):6405-10. Review.

16.

Impaired early B cell tolerance in patients with rheumatoid arthritis.

Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E.

J Exp Med. 2005 May 16;201(10):1659-67.

17.

Defective B cell tolerance checkpoints in systemic lupus erythematosus.

Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC.

J Exp Med. 2005 Mar 7;201(5):703-11. Epub 2005 Feb 28.

18.

B-cell kinetics in humans: rapid turnover of peripheral blood memory cells.

Macallan DC, Wallace DL, Zhang Y, Ghattas H, Asquith B, de Lara C, Worth A, Panayiotakopoulos G, Griffin GE, Tough DF, Beverley PC.

Blood. 2005 May 1;105(9):3633-40. Epub 2005 Jan 11.

19.

Predominant autoantibody production by early human B cell precursors.

Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC.

Science. 2003 Sep 5;301(5638):1374-7. Epub 2003 Aug 14.

20.

Transitional type 1 and 2 B lymphocyte subsets are differentially responsive to antigen receptor signaling.

Petro JB, Gerstein RM, Lowe J, Carter RS, Shinners N, Khan WN.

J Biol Chem. 2002 Dec 13;277(50):48009-19. Epub 2002 Sep 28.

Supplemental Content

Support Center